Clinical studies have reported retinal abnormalities, the persistence of peripheral avascular retina, ROP recurrence, retinal detachment, decreased systemic serum VEGF, and underdevelopment of other organ systems in ROP infants who received anti-VEGF therapy [2,3,7,8,9,10,11,16,17,18]. This evidence concerns the gene VEGFA and retinopathy of prematurity.